A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
NCT ID: NCT02386072
Last Updated: 2024-10-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1524 participants
OBSERVATIONAL
2015-01-05
2017-08-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
NCT02216214
Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women
NCT02981459
A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
NCT02138747
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
NCT03572231
Mirabegron and Urinary Urgency Incontinence
NCT02495389
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1. patients diagnosed with OAB taking mirabegron
patients diagnosed with OAB whose physician has decided to prescribe mirabegron as part of routine clinical practice
mirabegron
oral
2. patients diagnosed with OAB taking an antimuscarinic
patients diagnosed with OAB whose physician has decided to prescribe an antimuscarinic as part of routine clinical practice
antimuscarinic medication
oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
mirabegron
oral
antimuscarinic medication
oral
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Initiating a new course of treatment with mirabegron or antimuscarinic medication (including patch formulation) for OAB, which may be first course of any treatment for OAB, restart or switch from one drug to another
* Willing and able to complete PRO questionnaires with minimal assistance
Exclusion Criteria
* Use of more than one OAB medication at time of enrollment
* Patients whose OAB has been treated with onabotulinumtoxinA, sacral neuromodulation, percutaneous tibial nerve stimulation, external beam radiation (XRT), stents, surgery, or intermittent catheterization prior to or at time of enrollment
* Neurologic conditions associated with OAB symptoms
* Patients residing in a nursing home
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Scientific & Medical Affairs, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director Urology
Role: STUDY_DIRECTOR
Astellas Scientific & Medical Affairs, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site US1051
Birmingham, Alabama, United States
Site US1094
Birmingham, Alabama, United States
Site US1010
Huntsville, Alabama, United States
Site US1020
Mobile, Alabama, United States
Site US1006
Goodyear, Arizona, United States
Site US1036
Mesa, Arizona, United States
Site US1028
Phoenix, Arizona, United States
Site US1100
Tucson, Arizona, United States
Site US1083
Tucson, Arizona, United States
Site US1114
Little Rock, Arkansas, United States
Site US1061
Little Rock, Arkansas, United States
Site US1112
Garden Grove, California, United States
Site US1104
Sacramento, California, United States
Site US1013
Santa Ana, California, United States
Site US1090
Northglenn, Colorado, United States
Site US1050
Hialeah, Florida, United States
Site US1068
Miami, Florida, United States
Site US1079
Miami, Florida, United States
Site US1031
Miami, Florida, United States
Site US1032
Miami, Florida, United States
Site US1044
Miami, Florida, United States
Site US1018
Miami, Florida, United States
Site US1098
Miami, Florida, United States
Site US1075
Miami, Florida, United States
Site US1048
North Miami Beach, Florida, United States
Site US1093
Ocoee, Florida, United States
Site US1055
Pompano Beach, Florida, United States
Site US1042
Atlanta, Georgia, United States
Site US1035
Columbus, Georgia, United States
Site US1009
Marietta, Georgia, United States
Site US1016
Idaho Falls, Idaho, United States
Site US1046
Lake Barrington, Illinois, United States
Site US1019
Evansville, Indiana, United States
Site US1034
Evansville, Indiana, United States
Site US1097
Muncie, Indiana, United States
Site US1017
Council Bluffs, Iowa, United States
Site US1064
Overland Park, Kansas, United States
Site US1077
Lafayette, Louisiana, United States
Site US1058
Annapolis, Maryland, United States
Site US1088
Burlington, Massachusetts, United States
Site US1059
Fall River, Massachusetts, United States
Site US1076
Watertown, Massachusetts, United States
Site US1089
Worcester, Massachusetts, United States
Site US1062
Hamtramck, Michigan, United States
Site US1047
Hazelwood, Missouri, United States
Site US1082
St Louis, Missouri, United States
Site US1105
St Louis, Missouri, United States
Site US1102
Omaha, Nebraska, United States
Site US1039
Omaha, Nebraska, United States
Site US1043
Las Vegas, Nevada, United States
Site US1052
Las Vegas, Nevada, United States
Site US1085
New Brunswick, New Jersey, United States
Site US1001
Sicklerville, New Jersey, United States
Site US1008
Albuquerque, New Mexico, United States
Site US1103
Buffalo, New York, United States
Site US1096
Garden City, New York, United States
Site US1106
New York, New York, United States
Site US1111
New York, New York, United States
Site US1040
Newburgh, New York, United States
Site US1045
Poughkeepsie, New York, United States
Site US1060
Raleigh, North Carolina, United States
Site US1007
Hilliard, Ohio, United States
Site US1021
Downingtown, Pennsylvania, United States
Site US1070
Providence, Rhode Island, United States
Site US1004
Myrtle Beach, South Carolina, United States
Site US1084
Sioux Falls, South Dakota, United States
Site US1015
Clarksville, Tennessee, United States
Site US1037
Fort Worth, Texas, United States
Site US1080
Houston, Texas, United States
Site US1067
Houston, Texas, United States
Site US1057
Katy, Texas, United States
Site US1012
Plano, Texas, United States
Site US1099
Virginia Beach, Virginia, United States
Site US1086
Seattle, Washington, United States
Site US1071
Monroe, Wisconsin, United States
Site CA1026
Calgary, Alberta, Canada
Site CA1066
Coquitlam, British Columbia, Canada
Site CA1000
Victoria, British Columbia, Canada
Site CA1022
Burlington, Ontario, Canada
Site CA1029
Burlington, Ontario, Canada
Site CA1005
Greater Sudbury, Ontario, Canada
Site CA1072
Kingston, Ontario, Canada
Site CA1023
London, Ontario, Canada
Site CA1014
Mississauga, Ontario, Canada
Site CA1095
Oshawa, Ontario, Canada
Site CA1025
Oshawa, Ontario, Canada
Site CA1065
Ottawa, Ontario, Canada
Site CA1101
Richmond Hill, Ontario, Canada
Site CA1054
Scarborough Village, Ontario, Canada
Site CA1027
Toronto, Ontario, Canada
Site CA1092
Toronto, Ontario, Canada
Site CA1038
Pointe-Claire, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Schermer CR. Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE). Adv Ther. 2019 Aug;36(8):1906-1921. doi: 10.1007/s12325-019-00994-7. Epub 2019 Jun 20.
Rovner ES, Carlson KV, Deal AS, Nair KV, Oakkar EE, Park J, Gemmen E, Kristy RM, Gooch KL, Schermer CR. A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design, and methodology. Contemp Clin Trials. 2018 Jul;70:83-87. doi: 10.1016/j.cct.2018.05.006. Epub 2018 May 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
178-MA-1006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.